HomeCompareBFRA vs EPRT

BFRA vs EPRT: Dividend Comparison 2026

BFRA yields 4.72% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $37.1K in total portfolio value
10 years
BFRA
BFRA
● Live price
4.72%
Share price
$2.67
Annual div
$0.13
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.3K
Annual income
$638.40
Full BFRA calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — BFRA vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBFRAEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BFRA + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BFRA pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BFRA
Annual income on $10K today (after 15% tax)
$401.12/yr
After 10yr DRIP, annual income (after tax)
$542.64/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, EPRT beats the other by $10,652.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BFRA + EPRT for your $10,000?

BFRA: 50%EPRT: 50%
100% EPRT50/50100% BFRA
Portfolio after 10yr
$45.8K
Annual income
$6,904.63/yr
Blended yield
15.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

BFRA
Analyst Ratings
1
Buy
Consensus: Buy
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BFRA buys
0
EPRT buys
0
No recent congressional trades found for BFRA or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBFRAEPRT
Forward yield4.72%3.97%
Annual dividend / share$0.13$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$27.3K$64.3K
Annual income after 10y$638.40$13,170.85
Total dividends collected$5.6K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: BFRA vs EPRT ($10,000, DRIP)

YearBFRA PortfolioBFRA Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$11,172$471.91$11,212$512.01$40.00EPRT
2$12,447$492.72$12,689$692.09$242.00EPRT
3$13,831$513.03$14,521$944.30$690.00EPRT
4$15,332$532.80$16,841$1,302.88$1.5KEPRT
5$16,957$551.98$19,841$1,821.64$2.9KEPRT
6$18,715$570.55$23,818$2,587.47$5.1KEPRT
7$20,613$588.49$29,230$3,744.65$8.6KEPRT
8$22,662$605.78$36,816$5,540.38$14.2KEPRT
9$24,871$622.42$47,806$8,413.17$22.9KEPRT
10$27,250$638.40$64,324$13,170.85$37.1KEPRT

BFRA vs EPRT: Complete Analysis 2026

BFRAStock

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Full BFRA Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this BFRA vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BFRA vs SCHDBFRA vs JEPIBFRA vs OBFRA vs KOBFRA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.